nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP2A6—esophageal cancer	0.453	0.729	CbGaD
Dapagliflozin—ABCB1—esophageal cancer	0.169	0.271	CbGaD
Dapagliflozin—UGT2B4—pericardium—esophageal cancer	0.0246	0.388	CbGeAlD
Dapagliflozin—Carcinogenicity—Methotrexate—esophageal cancer	0.00981	0.0991	CcSEcCtD
Dapagliflozin—CYP2C9—Capecitabine—esophageal cancer	0.00781	0.433	CbGbCtD
Dapagliflozin—Venous thrombosis—Carboplatin—esophageal cancer	0.0068	0.0687	CcSEcCtD
Dapagliflozin—Fluid overload—Carboplatin—esophageal cancer	0.0059	0.0596	CcSEcCtD
Dapagliflozin—SLC5A4—digestive system—esophageal cancer	0.00564	0.0888	CbGeAlD
Dapagliflozin—Canagliflozin—ABCC2—esophageal cancer	0.00436	0.731	CrCbGaD
Dapagliflozin—SLC5A1—epithelium—esophageal cancer	0.00426	0.067	CbGeAlD
Dapagliflozin—Extravasation—Carboplatin—esophageal cancer	0.00421	0.0425	CcSEcCtD
Dapagliflozin—SLC5A1—bronchus—esophageal cancer	0.00419	0.066	CbGeAlD
Dapagliflozin—CYP2C9—Cisplatin—esophageal cancer	0.00393	0.218	CbGbCtD
Dapagliflozin—ABCB1—Cisplatin—esophageal cancer	0.00382	0.212	CbGbCtD
Dapagliflozin—SLC5A1—trachea—esophageal cancer	0.00377	0.0593	CbGeAlD
Dapagliflozin—Diuresis—Cisplatin—esophageal cancer	0.00347	0.0351	CcSEcCtD
Dapagliflozin—Haemolysis—Cisplatin—esophageal cancer	0.00339	0.0342	CcSEcCtD
Dapagliflozin—SLC5A1—digestive system—esophageal cancer	0.00324	0.051	CbGeAlD
Dapagliflozin—Angina unstable—Capecitabine—esophageal cancer	0.00314	0.0317	CcSEcCtD
Dapagliflozin—Phlebitis—Carboplatin—esophageal cancer	0.00309	0.0313	CcSEcCtD
Dapagliflozin—SLC5A1—lung—esophageal cancer	0.00271	0.0426	CbGeAlD
Dapagliflozin—UGT2B4—lung—esophageal cancer	0.00249	0.0392	CbGeAlD
Dapagliflozin—ABCB1—Methotrexate—esophageal cancer	0.00248	0.137	CbGbCtD
Dapagliflozin—UGT1A9—digestive system—esophageal cancer	0.00204	0.0321	CbGeAlD
Dapagliflozin—Venous thrombosis—Cisplatin—esophageal cancer	0.002	0.0202	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Cisplatin—esophageal cancer	0.00175	0.0177	CcSEcCtD
Dapagliflozin—Fluid overload—Cisplatin—esophageal cancer	0.00173	0.0175	CcSEcCtD
Dapagliflozin—UGT2B7—digestive system—esophageal cancer	0.00164	0.0259	CbGeAlD
Dapagliflozin—Canagliflozin—ABCB1—esophageal cancer	0.00161	0.269	CrCbGaD
Dapagliflozin—Venous thrombosis—Capecitabine—esophageal cancer	0.00147	0.0149	CcSEcCtD
Dapagliflozin—Infection—Carboplatin—esophageal cancer	0.0013	0.0131	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Capecitabine—esophageal cancer	0.00129	0.013	CcSEcCtD
Dapagliflozin—Extravasation—Cisplatin—esophageal cancer	0.00123	0.0125	CcSEcCtD
Dapagliflozin—Body temperature increased—Carboplatin—esophageal cancer	0.00104	0.0105	CcSEcCtD
Dapagliflozin—Fungal infection—Capecitabine—esophageal cancer	0.00103	0.0104	CcSEcCtD
Dapagliflozin—Multiple fractures—Methotrexate—esophageal cancer	0.00102	0.0103	CcSEcCtD
Dapagliflozin—Fracture—Methotrexate—esophageal cancer	0.00102	0.0103	CcSEcCtD
Dapagliflozin—CYP2A6—lung—esophageal cancer	0.000984	0.0155	CbGeAlD
Dapagliflozin—Phlebitis—Cisplatin—esophageal cancer	0.000907	0.00917	CcSEcCtD
Dapagliflozin—Polyuria—Cisplatin—esophageal cancer	0.00089	0.00899	CcSEcCtD
Dapagliflozin—Nocturia—Capecitabine—esophageal cancer	0.000856	0.00865	CcSEcCtD
Dapagliflozin—Lung disorder—Methotrexate—esophageal cancer	0.000835	0.00843	CcSEcCtD
Dapagliflozin—CYP1A1—epithelium—esophageal cancer	0.000802	0.0126	CbGeAlD
Dapagliflozin—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000798	0.00806	CcSEcCtD
Dapagliflozin—CYP1A1—bronchus—esophageal cancer	0.00079	0.0124	CbGeAlD
Dapagliflozin—Hyponatraemia—Cisplatin—esophageal cancer	0.000785	0.00793	CcSEcCtD
Dapagliflozin—Fungal infection—Methotrexate—esophageal cancer	0.000765	0.00773	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Cisplatin—esophageal cancer	0.000732	0.0074	CcSEcCtD
Dapagliflozin—Dehydration—Cisplatin—esophageal cancer	0.000727	0.00734	CcSEcCtD
Dapagliflozin—Urine output increased—Capecitabine—esophageal cancer	0.000718	0.00725	CcSEcCtD
Dapagliflozin—Neoplasm—Capecitabine—esophageal cancer	0.000718	0.00725	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Cisplatin—esophageal cancer	0.000714	0.00721	CcSEcCtD
Dapagliflozin—CYP1A1—trachea—esophageal cancer	0.000709	0.0112	CbGeAlD
Dapagliflozin—Nasopharyngitis—Cisplatin—esophageal cancer	0.000699	0.00706	CcSEcCtD
Dapagliflozin—Extravasation—Methotrexate—esophageal cancer	0.000677	0.00684	CcSEcCtD
Dapagliflozin—Phlebitis—Capecitabine—esophageal cancer	0.000669	0.00676	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Capecitabine—esophageal cancer	0.000662	0.00669	CcSEcCtD
Dapagliflozin—Polyuria—Capecitabine—esophageal cancer	0.000656	0.00663	CcSEcCtD
Dapagliflozin—CYP1A2—digestive system—esophageal cancer	0.000619	0.00974	CbGeAlD
Dapagliflozin—CYP1A1—digestive system—esophageal cancer	0.00061	0.00961	CbGeAlD
Dapagliflozin—Thirst—Capecitabine—esophageal cancer	0.000605	0.00612	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000594	0.006	CcSEcCtD
Dapagliflozin—Renal failure—Cisplatin—esophageal cancer	0.000592	0.00598	CcSEcCtD
Dapagliflozin—Myocardial infarction—Cisplatin—esophageal cancer	0.00059	0.00597	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000588	0.00594	CcSEcCtD
Dapagliflozin—CYP2C9—digestive system—esophageal cancer	0.000587	0.00924	CbGeAlD
Dapagliflozin—Hyponatraemia—Capecitabine—esophageal cancer	0.000579	0.00585	CcSEcCtD
Dapagliflozin—Pain in extremity—Capecitabine—esophageal cancer	0.000576	0.00582	CcSEcCtD
Dapagliflozin—Vaginal infection—Methotrexate—esophageal cancer	0.000558	0.00564	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Capecitabine—esophageal cancer	0.00054	0.00545	CcSEcCtD
Dapagliflozin—Dehydration—Capecitabine—esophageal cancer	0.000536	0.00541	CcSEcCtD
Dapagliflozin—Neoplasm—Methotrexate—esophageal cancer	0.000534	0.0054	CcSEcCtD
Dapagliflozin—Urine output increased—Methotrexate—esophageal cancer	0.000534	0.0054	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Cisplatin—esophageal cancer	0.000534	0.0054	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Cisplatin—esophageal cancer	0.000531	0.00537	CcSEcCtD
Dapagliflozin—Urethral disorder—Cisplatin—esophageal cancer	0.00053	0.00536	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000526	0.00532	CcSEcCtD
Dapagliflozin—CYP1A2—lung—esophageal cancer	0.000517	0.00813	CbGeAlD
Dapagliflozin—Nasopharyngitis—Capecitabine—esophageal cancer	0.000515	0.00521	CcSEcCtD
Dapagliflozin—CYP1A1—lung—esophageal cancer	0.00051	0.00802	CbGeAlD
Dapagliflozin—Influenza—Capecitabine—esophageal cancer	0.000498	0.00503	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Methotrexate—esophageal cancer	0.000493	0.00498	CcSEcCtD
Dapagliflozin—Polyuria—Methotrexate—esophageal cancer	0.000489	0.00494	CcSEcCtD
Dapagliflozin—Angina pectoris—Capecitabine—esophageal cancer	0.000485	0.0049	CcSEcCtD
Dapagliflozin—Malnutrition—Cisplatin—esophageal cancer	0.000471	0.00476	CcSEcCtD
Dapagliflozin—Dysuria—Capecitabine—esophageal cancer	0.000466	0.00471	CcSEcCtD
Dapagliflozin—CYP3A4—digestive system—esophageal cancer	0.000448	0.00705	CbGeAlD
Dapagliflozin—Infestation—Capecitabine—esophageal cancer	0.000444	0.00449	CcSEcCtD
Dapagliflozin—Infestation NOS—Capecitabine—esophageal cancer	0.000444	0.00449	CcSEcCtD
Dapagliflozin—CYP2D6—digestive system—esophageal cancer	0.000441	0.00694	CbGeAlD
Dapagliflozin—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000438	0.00442	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000438	0.00442	CcSEcCtD
Dapagliflozin—Renal failure—Capecitabine—esophageal cancer	0.000436	0.00441	CcSEcCtD
Dapagliflozin—Myocardial infarction—Capecitabine—esophageal cancer	0.000435	0.0044	CcSEcCtD
Dapagliflozin—Urinary tract infection—Capecitabine—esophageal cancer	0.000432	0.00436	CcSEcCtD
Dapagliflozin—ABCB1—epithelium—esophageal cancer	0.000417	0.00656	CbGeAlD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000398	0.00402	CcSEcCtD
Dapagliflozin—Discomfort—Cisplatin—esophageal cancer	0.000396	0.004	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Capecitabine—esophageal cancer	0.000394	0.00398	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Capecitabine—esophageal cancer	0.000392	0.00396	CcSEcCtD
Dapagliflozin—Urethral disorder—Capecitabine—esophageal cancer	0.000391	0.00395	CcSEcCtD
Dapagliflozin—Oedema—Cisplatin—esophageal cancer	0.000384	0.00388	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Cisplatin—esophageal cancer	0.000384	0.00388	CcSEcCtD
Dapagliflozin—Infection—Cisplatin—esophageal cancer	0.000382	0.00386	CcSEcCtD
Dapagliflozin—Skin disorder—Cisplatin—esophageal cancer	0.000373	0.00377	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Cisplatin—esophageal cancer	0.000371	0.00375	CcSEcCtD
Dapagliflozin—ABCB1—trachea—esophageal cancer	0.000368	0.0058	CbGeAlD
Dapagliflozin—Hypotension—Cisplatin—esophageal cancer	0.000359	0.00363	CcSEcCtD
Dapagliflozin—CYP1A1—lymph node—esophageal cancer	0.000349	0.00549	CbGeAlD
Dapagliflozin—Malnutrition—Capecitabine—esophageal cancer	0.000347	0.00351	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—esophageal cancer	0.000347	0.0035	CcSEcCtD
Dapagliflozin—Back pain—Capecitabine—esophageal cancer	0.000336	0.00339	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000332	0.00335	CcSEcCtD
Dapagliflozin—Infestation NOS—Methotrexate—esophageal cancer	0.000331	0.00334	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—esophageal cancer	0.000331	0.00334	CcSEcCtD
Dapagliflozin—Renal failure—Methotrexate—esophageal cancer	0.000325	0.00328	CcSEcCtD
Dapagliflozin—ABCB1—digestive system—esophageal cancer	0.000317	0.00499	CbGeAlD
Dapagliflozin—Body temperature increased—Cisplatin—esophageal cancer	0.000304	0.00307	CcSEcCtD
Dapagliflozin—Hypertension—Capecitabine—esophageal cancer	0.0003	0.00303	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000293	0.00296	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Methotrexate—esophageal cancer	0.000293	0.00296	CcSEcCtD
Dapagliflozin—Discomfort—Capecitabine—esophageal cancer	0.000292	0.00295	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—esophageal cancer	0.000291	0.00294	CcSEcCtD
Dapagliflozin—Oedema—Capecitabine—esophageal cancer	0.000283	0.00286	CcSEcCtD
Dapagliflozin—Hypersensitivity—Cisplatin—esophageal cancer	0.000283	0.00286	CcSEcCtD
Dapagliflozin—Infection—Capecitabine—esophageal cancer	0.000281	0.00284	CcSEcCtD
Dapagliflozin—Skin disorder—Capecitabine—esophageal cancer	0.000275	0.00278	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Capecitabine—esophageal cancer	0.000274	0.00277	CcSEcCtD
Dapagliflozin—ABCB1—lung—esophageal cancer	0.000265	0.00417	CbGeAlD
Dapagliflozin—Hypotension—Capecitabine—esophageal cancer	0.000265	0.00267	CcSEcCtD
Dapagliflozin—Malnutrition—Methotrexate—esophageal cancer	0.000258	0.00261	CcSEcCtD
Dapagliflozin—Back pain—Methotrexate—esophageal cancer	0.00025	0.00252	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000244	0.00247	CcSEcCtD
Dapagliflozin—Rash—Cisplatin—esophageal cancer	0.000242	0.00245	CcSEcCtD
Dapagliflozin—Constipation—Capecitabine—esophageal cancer	0.000242	0.00245	CcSEcCtD
Dapagliflozin—Dermatitis—Cisplatin—esophageal cancer	0.000242	0.00245	CcSEcCtD
Dapagliflozin—Nausea—Cisplatin—esophageal cancer	0.000228	0.00231	CcSEcCtD
Dapagliflozin—Urticaria—Capecitabine—esophageal cancer	0.000225	0.00227	CcSEcCtD
Dapagliflozin—Body temperature increased—Capecitabine—esophageal cancer	0.000224	0.00226	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000218	0.00221	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—esophageal cancer	0.000217	0.0022	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—esophageal cancer	0.000211	0.00213	CcSEcCtD
Dapagliflozin—Infection—Methotrexate—esophageal cancer	0.000209	0.00212	CcSEcCtD
Dapagliflozin—Hypersensitivity—Capecitabine—esophageal cancer	0.000209	0.00211	CcSEcCtD
Dapagliflozin—Skin disorder—Methotrexate—esophageal cancer	0.000205	0.00207	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—esophageal cancer	0.000204	0.00206	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—esophageal cancer	0.000197	0.00199	CcSEcCtD
Dapagliflozin—Dizziness—Capecitabine—esophageal cancer	0.000187	0.00189	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000182	0.00184	CcSEcCtD
Dapagliflozin—ABCB1—lymph node—esophageal cancer	0.000181	0.00285	CbGeAlD
Dapagliflozin—Rash—Capecitabine—esophageal cancer	0.000179	0.0018	CcSEcCtD
Dapagliflozin—Dermatitis—Capecitabine—esophageal cancer	0.000178	0.0018	CcSEcCtD
Dapagliflozin—Headache—Capecitabine—esophageal cancer	0.000177	0.00179	CcSEcCtD
Dapagliflozin—Nausea—Capecitabine—esophageal cancer	0.000168	0.0017	CcSEcCtD
Dapagliflozin—Urticaria—Methotrexate—esophageal cancer	0.000167	0.00169	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—esophageal cancer	0.000167	0.00168	CcSEcCtD
Dapagliflozin—Hypersensitivity—Methotrexate—esophageal cancer	0.000155	0.00157	CcSEcCtD
Dapagliflozin—Dizziness—Methotrexate—esophageal cancer	0.000139	0.00141	CcSEcCtD
Dapagliflozin—Rash—Methotrexate—esophageal cancer	0.000133	0.00134	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—esophageal cancer	0.000133	0.00134	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—esophageal cancer	0.000132	0.00133	CcSEcCtD
Dapagliflozin—Nausea—Methotrexate—esophageal cancer	0.000125	0.00127	CcSEcCtD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	1.87e-05	9.72e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	1.86e-05	9.68e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	1.82e-05	9.51e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC10A2—esophageal cancer	1.78e-05	9.28e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CA1—esophageal cancer	1.78e-05	9.28e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GNG7—esophageal cancer	1.78e-05	9.28e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—BLVRB—esophageal cancer	1.78e-05	9.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC52A3—esophageal cancer	1.78e-05	9.25e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CA1—esophageal cancer	1.77e-05	9.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC10A2—esophageal cancer	1.77e-05	9.2e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ADH1B—esophageal cancer	1.77e-05	9.2e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—HMOX1—esophageal cancer	1.73e-05	9.03e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CA2—esophageal cancer	1.73e-05	9.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TYMP—esophageal cancer	1.69e-05	8.79e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ALDH2—esophageal cancer	1.67e-05	8.7e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ABCB1—esophageal cancer	1.66e-05	8.67e-05	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—EP300—esophageal cancer	1.66e-05	8.66e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.66e-05	8.65e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.65e-05	8.59e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP26A1—esophageal cancer	1.64e-05	8.55e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP1B1—esophageal cancer	1.64e-05	8.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CA2—esophageal cancer	1.63e-05	8.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CA2—esophageal cancer	1.62e-05	8.42e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ADH7—esophageal cancer	1.61e-05	8.38e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PLCE1—esophageal cancer	1.61e-05	8.38e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALOX15—esophageal cancer	1.6e-05	8.33e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.59e-05	8.31e-05	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PIK3CA—esophageal cancer	1.59e-05	8.3e-05	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PIK3CA—esophageal cancer	1.59e-05	8.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTT1—esophageal cancer	1.59e-05	8.27e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	1.59e-05	8.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.58e-05	8.23e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP19A1—esophageal cancer	1.54e-05	8.04e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTO1—esophageal cancer	1.53e-05	7.95e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TPI1—esophageal cancer	1.53e-05	7.95e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.52e-05	7.91e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PLCE1—esophageal cancer	1.52e-05	7.89e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ADH7—esophageal cancer	1.52e-05	7.89e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CA1—esophageal cancer	1.51e-05	7.87e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC10A2—esophageal cancer	1.51e-05	7.87e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PLCE1—esophageal cancer	1.5e-05	7.83e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ADH7—esophageal cancer	1.5e-05	7.83e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS1—esophageal cancer	1.49e-05	7.75e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ENO1—esophageal cancer	1.49e-05	7.75e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.48e-05	7.74e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PSME1—esophageal cancer	1.47e-05	7.64e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PSME2—esophageal cancer	1.47e-05	7.64e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALDOB—esophageal cancer	1.46e-05	7.62e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ADH1B—esophageal cancer	1.41e-05	7.35e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GAPDH—esophageal cancer	1.41e-05	7.34e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—HMOX1—esophageal cancer	1.41e-05	7.34e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CRABP1—esophageal cancer	1.4e-05	7.27e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.38e-05	7.2e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CA2—esophageal cancer	1.38e-05	7.19e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.38e-05	7.19e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.37e-05	7.14e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.37e-05	7.14e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ABCB1—esophageal cancer	1.35e-05	7.04e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.35e-05	7.03e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TYMP—esophageal cancer	1.35e-05	7.02e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ADH1B—esophageal cancer	1.33e-05	6.92e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GNG7—esophageal cancer	1.33e-05	6.92e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.32e-05	6.89e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ADH1B—esophageal cancer	1.32e-05	6.86e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.31e-05	6.83e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.29e-05	6.74e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PLCE1—esophageal cancer	1.28e-05	6.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ADH7—esophageal cancer	1.28e-05	6.69e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALOX15—esophageal cancer	1.28e-05	6.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TYMP—esophageal cancer	1.27e-05	6.62e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.27e-05	6.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP1B1—esophageal cancer	1.27e-05	6.59e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TYMP—esophageal cancer	1.26e-05	6.56e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALDH2—esophageal cancer	1.24e-05	6.48e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP26A1—esophageal cancer	1.24e-05	6.44e-05	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CA—esophageal cancer	1.23e-05	6.41e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP26A1—esophageal cancer	1.22e-05	6.38e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTO1—esophageal cancer	1.22e-05	6.35e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TPI1—esophageal cancer	1.22e-05	6.35e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALOX15—esophageal cancer	1.2e-05	6.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALOX15—esophageal cancer	1.19e-05	6.22e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP19A1—esophageal cancer	1.19e-05	6.2e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTT1—esophageal cancer	1.18e-05	6.16e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP2A6—esophageal cancer	1.17e-05	6.09e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALDOB—esophageal cancer	1.17e-05	6.09e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.17e-05	6.07e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CA1—esophageal cancer	1.17e-05	6.07e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.16e-05	6.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TPI1—esophageal cancer	1.15e-05	5.98e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTO1—esophageal cancer	1.15e-05	5.98e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTO1—esophageal cancer	1.14e-05	5.93e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TPI1—esophageal cancer	1.14e-05	5.93e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ADH1B—esophageal cancer	1.13e-05	5.86e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GAPDH—esophageal cancer	1.12e-05	5.86e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.12e-05	5.85e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CRABP1—esophageal cancer	1.11e-05	5.81e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CREBBP—esophageal cancer	1.11e-05	5.79e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ENO1—esophageal cancer	1.11e-05	5.78e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS1—esophageal cancer	1.11e-05	5.78e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALDOB—esophageal cancer	1.1e-05	5.74e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PSME1—esophageal cancer	1.09e-05	5.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PSME2—esophageal cancer	1.09e-05	5.69e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.09e-05	5.69e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.09e-05	5.66e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—HMOX1—esophageal cancer	1.09e-05	5.66e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TYMP—esophageal cancer	1.08e-05	5.6e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CA2—esophageal cancer	1.07e-05	5.55e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GNG7—esophageal cancer	1.06e-05	5.52e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GAPDH—esophageal cancer	1.06e-05	5.52e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.05e-05	5.47e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.05e-05	5.47e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.05e-05	5.45e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ABCB1—esophageal cancer	1.04e-05	5.43e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.04e-05	5.42e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.02e-05	5.32e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.02e-05	5.31e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GNG7—esophageal cancer	9.99e-06	5.2e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—NOS3—esophageal cancer	9.95e-06	5.19e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALDH2—esophageal cancer	9.93e-06	5.18e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PLCE1—esophageal cancer	9.91e-06	5.16e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ADH7—esophageal cancer	9.91e-06	5.16e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GNG7—esophageal cancer	9.9e-06	5.16e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTO1—esophageal cancer	9.73e-06	5.07e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TPI1—esophageal cancer	9.73e-06	5.07e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	9.54e-06	4.97e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTT1—esophageal cancer	9.45e-06	4.92e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP1B1—esophageal cancer	9.43e-06	4.91e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALDH2—esophageal cancer	9.36e-06	4.88e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP2A6—esophageal cancer	9.34e-06	4.87e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALDOB—esophageal cancer	9.33e-06	4.86e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALDH2—esophageal cancer	9.28e-06	4.84e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTGS2—esophageal cancer	9.1e-06	4.74e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CREBBP—esophageal cancer	9.03e-06	4.71e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GAPDH—esophageal cancer	8.98e-06	4.68e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTT1—esophageal cancer	8.9e-06	4.64e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CRABP1—esophageal cancer	8.9e-06	4.64e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP19A1—esophageal cancer	8.86e-06	4.62e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ENO1—esophageal cancer	8.85e-06	4.61e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS1—esophageal cancer	8.85e-06	4.61e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	8.85e-06	4.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTT1—esophageal cancer	8.83e-06	4.6e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP2A6—esophageal cancer	8.8e-06	4.59e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP2A6—esophageal cancer	8.73e-06	4.55e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PSME1—esophageal cancer	8.72e-06	4.55e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PSME2—esophageal cancer	8.72e-06	4.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.69e-06	4.53e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ADH1B—esophageal cancer	8.69e-06	4.53e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GNG7—esophageal cancer	8.46e-06	4.41e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS1—esophageal cancer	8.34e-06	4.35e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ENO1—esophageal cancer	8.34e-06	4.35e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TYMP—esophageal cancer	8.3e-06	4.33e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ENO1—esophageal cancer	8.27e-06	4.31e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS1—esophageal cancer	8.27e-06	4.31e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PSME2—esophageal cancer	8.22e-06	4.28e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PSME1—esophageal cancer	8.22e-06	4.28e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PSME2—esophageal cancer	8.15e-06	4.25e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PSME1—esophageal cancer	8.15e-06	4.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HMOX1—esophageal cancer	8.09e-06	4.21e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—NOS3—esophageal cancer	8.09e-06	4.21e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP26A1—esophageal cancer	8.08e-06	4.21e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.93e-06	4.13e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALDH2—esophageal cancer	7.93e-06	4.13e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALOX15—esophageal cancer	7.87e-06	4.1e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ABCB1—esophageal cancer	7.76e-06	4.04e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—EP300—esophageal cancer	7.57e-06	3.94e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTT1—esophageal cancer	7.54e-06	3.93e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1B1—esophageal cancer	7.53e-06	3.92e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TPI1—esophageal cancer	7.51e-06	3.91e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTO1—esophageal cancer	7.51e-06	3.91e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP2A6—esophageal cancer	7.46e-06	3.88e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7.43e-06	3.87e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—esophageal cancer	7.4e-06	3.85e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALDOB—esophageal cancer	7.2e-06	3.75e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.12e-06	3.71e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1B1—esophageal cancer	7.09e-06	3.7e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP19A1—esophageal cancer	7.08e-06	3.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ENO1—esophageal cancer	7.07e-06	3.68e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS1—esophageal cancer	7.07e-06	3.68e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1B1—esophageal cancer	7.03e-06	3.66e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PSME2—esophageal cancer	6.96e-06	3.63e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PSME1—esophageal cancer	6.96e-06	3.63e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CREBBP—esophageal cancer	6.96e-06	3.63e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GAPDH—esophageal cancer	6.93e-06	3.61e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CRABP1—esophageal cancer	6.87e-06	3.58e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP19A1—esophageal cancer	6.67e-06	3.48e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP19A1—esophageal cancer	6.61e-06	3.45e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GNG7—esophageal cancer	6.53e-06	3.4e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HMOX1—esophageal cancer	6.46e-06	3.37e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NOS3—esophageal cancer	6.23e-06	3.25e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—EP300—esophageal cancer	6.15e-06	3.21e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALDH2—esophageal cancer	6.12e-06	3.19e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HMOX1—esophageal cancer	6.09e-06	3.17e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.08e-06	3.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HMOX1—esophageal cancer	6.03e-06	3.14e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP1B1—esophageal cancer	6.01e-06	3.13e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.92e-06	3.08e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.87e-06	3.06e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ABCB1—esophageal cancer	5.84e-06	3.04e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTT1—esophageal cancer	5.82e-06	3.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ABCB1—esophageal cancer	5.79e-06	3.02e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2A6—esophageal cancer	5.75e-06	3e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—esophageal cancer	5.7e-06	2.97e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP19A1—esophageal cancer	5.65e-06	2.94e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CA—esophageal cancer	5.6e-06	2.92e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.45e-06	2.84e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ENO1—esophageal cancer	5.45e-06	2.84e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PSME2—esophageal cancer	5.38e-06	2.8e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PSME1—esophageal cancer	5.38e-06	2.8e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CREBBP—esophageal cancer	5.19e-06	2.7e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HMOX1—esophageal cancer	5.16e-06	2.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.06e-06	2.64e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCB1—esophageal cancer	4.95e-06	2.58e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—EP300—esophageal cancer	4.74e-06	2.47e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NOS3—esophageal cancer	4.64e-06	2.42e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.64e-06	2.42e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CA—esophageal cancer	4.55e-06	2.37e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.38e-06	2.28e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.36e-06	2.27e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—esophageal cancer	4.25e-06	2.21e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CREBBP—esophageal cancer	4.14e-06	2.16e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.98e-06	2.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.9e-06	2.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CREBBP—esophageal cancer	3.87e-06	2.02e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.82e-06	1.99e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.74e-06	1.95e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NOS3—esophageal cancer	3.71e-06	1.93e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—EP300—esophageal cancer	3.53e-06	1.84e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CA—esophageal cancer	3.51e-06	1.83e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NOS3—esophageal cancer	3.5e-06	1.82e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NOS3—esophageal cancer	3.47e-06	1.81e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—esophageal cancer	3.39e-06	1.77e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.31e-06	1.72e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—esophageal cancer	3.2e-06	1.67e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—esophageal cancer	3.17e-06	1.65e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NOS3—esophageal cancer	2.96e-06	1.54e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—EP300—esophageal cancer	2.82e-06	1.47e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.71e-06	1.41e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—EP300—esophageal cancer	2.66e-06	1.39e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—EP300—esophageal cancer	2.64e-06	1.37e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CA—esophageal cancer	2.61e-06	1.36e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.55e-06	1.33e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NOS3—esophageal cancer	2.29e-06	1.19e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—EP300—esophageal cancer	2.25e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.09e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.09e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.97e-06	1.02e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.95e-06	1.02e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—EP300—esophageal cancer	1.74e-06	9.06e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.67e-06	8.68e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.29e-06	6.7e-06	CbGpPWpGaD
